ORAMED PHARMACEUTICALS INC. 8-K

What Happened
Oramed Pharmaceuticals Inc. filed an 8-K (Dec 31, 2025) reporting that Scilex Holding Company repurchased all subject warrants originally covered by an Option Agreement dated July 22, 2025. The subject warrants covered 6,500,000 shares of Scilex common stock at a $0.01 exercise price. Scilex completed the repurchase in two tranches, and Oramed received aggregate payments of $28,500,000 in connection with the transaction.

Key Details

• Option Agreement entered July 22, 2025; previously disclosed in Oramed’s July 23, 2025 8-K.
• First tranche: on Sept 30, 2025 Scilex repurchased warrants to buy 3,130,000 shares for $13,000,000; an initial option fee of $750,000 was paid before that purchase.
• Second tranche: on Dec 30, 2025 Scilex repurchased warrants to buy 3,370,000 shares for $14,000,000 (inclusive of certain prepayments) plus a second option fee of $750,000.
• Total cash received by Oramed from Scilex for the repurchase and option fees: $28,500,000.

Why It Matters
For investors, this filing documents a completed cash inflow of $28.5 million to Oramed from Scilex, which increases Oramed’s liquidity and removes its position in the 6.5 million Scilex warrants. The transaction changes Oramed’s exposure to potential future upside from those specific Scilex warrants while providing immediate cash proceeds.